Fortis Healthcare Limited — Important, 16-01-2025: General Updates

Fortis Healthcare Limited has executed agreements for acquiring a total of 31.52% of Agilus Diagnostics Limited from various private equity investors, including a 15.86% stake from NJBIF and an 8.05% stake from Resurgence. This significant move will increase Fortis's ownership in Agilus to 89.2%. The total cash consideration for these acquisitions is approximately INR 1,44,25,56,220.68, equating to INR 719.20 per share.

Agilus specializes in diagnostic services with consistent growth in revenue over the past three years, reporting standalone revenues of Rs. 85,880.88 Cr for FY 2023-24. This acquisition aligns Fortis with Agilus's strong national presence across 407 labs, anticipating benefits from scale and integration. Given Agilus's foothold in diagnostics and the expected completion date of January 20, 2025, this acquisition signals a positive outlook for Fortis, enhancing its competitive edge in the healthcare sector. Investors should monitor the integration process and its impact on future performance.